Financings In Brief: ImClone Systems
Executive Summary
ImClone Systems: Oracle Partners invest $4 mil. in ImClone through $2.5 mil. loan, purchase of common stock and issuance of warrants, the New York City-based cancer therapeutics firm announces. ImClone's lead product C225, an epidermal growth factor receptor antagonist which is thought to induce apoptosis in cancerous cells, is in PhaseIb/IIa trials...